{"id":13657,"date":"2023-09-20T00:59:00","date_gmt":"2023-09-19T16:59:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13657"},"modified":"2024-11-20T01:03:41","modified_gmt":"2024-11-19T17:03:41","slug":"eli-lilly-partners-with-boundless-bio-to-develop-chk1-inhibitor-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13657","title":{"rendered":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors"},"content":{"rendered":"\n

Eli Lilly (NYSE: LLY<\/a>) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless’s CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly’s CDK4\/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate as the first extrachromosomal DNA-directed therapy (ecDTx) for this cancer type.<\/p>\n\n\n\n

Clinical Development and Trial Details<\/strong>
Boundless Bio is currently conducting a Phase I\/II trial for BBI-355, which is being tested as a monotherapy and in combination with selected targeted drugs. The trial will now include Verzenio, supplied by Lilly without charge, as part of the combination therapy. This partnership is expected to accelerate the clinical development of BBI-355 and expand the treatment options for patients with specific types of cancer.<\/p>\n\n\n\n

Implications of the Partnership<\/strong>
The collaboration between Eli Lilly and Boundless Bio underscores the growing interest in precision oncology and the potential for combination therapies to address complex cancer cases. By combining a CDK4\/6 inhibitor with a CHK1 inhibitor, the partnership aims to enhance the efficacy of treatments for patients with oncogene-amplified tumors, offering a new approach to cancer management.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2202,16,62,199,911],"class_list":["post-13657","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-boundless-bio","tag-cancer","tag-clinical-trial-approval-initiation","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"\nEli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless's CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly's CDK4\/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate as the first extrachromosomal DNA-directed therapy (ecDTx) for this cancer type.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13657\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13657\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-19T16:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T17:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors\",\"datePublished\":\"2023-09-19T16:59:00+00:00\",\"dateModified\":\"2024-11-19T17:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Boundless Bio\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13657#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13657\",\"name\":\"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-19T16:59:00+00:00\",\"dateModified\":\"2024-11-19T17:03:41+00:00\",\"description\":\"Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless's CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly's CDK4\\\/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate as the first extrachromosomal DNA-directed therapy (ecDTx) for this cancer type.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13657\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13657#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors - Insight, China's Pharmaceutical Industry","description":"Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless's CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly's CDK4\/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate as the first extrachromosomal DNA-directed therapy (ecDTx) for this cancer type.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13657","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13657","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-19T16:59:00+00:00","article_modified_time":"2024-11-19T17:03:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13657#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13657"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors","datePublished":"2023-09-19T16:59:00+00:00","dateModified":"2024-11-19T17:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13657"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Boundless Bio","Cancer","Clinical trial approval \/ initiation","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13657#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13657","url":"https:\/\/flcube.com\/?p=13657","name":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-19T16:59:00+00:00","dateModified":"2024-11-19T17:03:41+00:00","description":"Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless's CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly's CDK4\/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate as the first extrachromosomal DNA-directed therapy (ecDTx) for this cancer type.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13657#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13657"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13657#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13657"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13657\/revisions"}],"predecessor-version":[{"id":13659,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13657\/revisions\/13659"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}